We have developed a simple fluorescent assay for detection of phospholipase A 2 (PLA 2 ) activity in zebrafish embryos that utilizes a fluorescent phosphatidylcholine substrate. By using this assay in conjunction with selective PLA 2 inhibitors and Western blot analysis, we identified the principal activity in zebrafish embryogenesis as characteristic of the Ca 2؉ -dependent cytosolic PLA 2 (cPLA 2 ) subtype. Embryonic cPLA 2 activity remained constant from the 1-cell stage until the onset of somitogenesis, at which time it increased sharply. This increase was preceded by the expression of a previously identified zebrafish cPLA 2 homologue (Nalefski, E.,
We have developed a simple fluorescent assay for detection of phospholipase A 2 (PLA 2 ) activity in zebrafish embryos that utilizes a fluorescent phosphatidylcholine substrate. By using this assay in conjunction with selective PLA 2 1 catalyzes the hydrolysis of the sn-2 fatty acyl bond of glycerophospholipids to liberate lysophospholipid and free fatty acid, both potential precursors to lipid signaling molecules (2) (3) (4) . The family of PLA 2 enzymes is diverse and has been shown to function in digestion of lipids, microbial degradation, inflammation, cell signaling, and membrane remodeling (5) . PLA 2 enzymes are primarily classified on the basis of their Ca 2ϩ dependence and whether they are cytosolic or secreted (5) . The Ca 2ϩ -dependent high molecular mass (85 kDa) cytosolic PLA 2 (cPLA 2 ) and some of the lower molecular mass (28 -40 kDa) Ca 2ϩ -independent cytosolic PLA 2 s (iPLA 2 s) exhibit a substrate preference for phospholipids with arachidonic acid (AA) at the sn-2 position (6 -8) . This is of particular significance because AA released by PLA 2 activity is the precursor for the synthesis of eicosanoids, potent lipid mediators that include prostaglandins and leukotrienes (2, 6, 9) . In contrast, secreted PLA 2 s (sPLA 2 s) and the 80-kDa cytosolic iPLA 2 can liberate AA, but they exhibit little preference for sn-2 AA (5) .
A number of studies have explored the contributions of different PLA 2 isoforms on total AA release and eicosanoid synthesis. In mice in which the cPLA 2 gene was disrupted by targeted mutagenesis, the production of prostaglandins, leukotrienes, and platelet-activating factor were all reduced in peritoneal macrophages (10, 11) . Whereas the 80-kDa cytosolic iPLA 2 can augment cPLA 2 -induced AA release, work by Dennis and co-workers (12, 13) suggests that its primary role is to remodel phospholipids. Overexpression studies in tissue culture support the model that following pro-inflammatory stimuli cPLA 2 activation triggers the immediate release of AA (within 30 min) that is essential for a later, sPLA 2 -induced, phase of AA release (measured over a 10-h period) (14 -16) . Whether or not sPLA 2 plays a central role in eicosanoid production, the above studies indicate that cPLA 2 is an important mediator of stimulus-induced AA release and subsequent eicosanoid synthesis.
The cPLA 2 protein is ubiquitously expressed in all adult human tissues (17) but is subject to complex regulation that enables the immediate generation of eicosanoids in response to physiologic stimuli (18 -20) . For example, in cell culture, a number of receptor agonists (e.g. interleukin-1, ATP, and thrombin) increase cytosolic calcium. Calcium promotes the rapid translocation of cPLA 2 from the cytosol to the membranes of the nuclear envelope where it interacts with phospholipid substrates (1, 20 -22) . Activity can be further enhanced by increased serine phosphorylation of cPLA 2 by p42/p44 mitogenactivated protein kinases (18, 19, 23) .
Although eicosanoids, the products of PLA 2 activity, are well known mediators of inflammatory and allergic responses in mammals (24) and teleosts (25, 26) , their function during embryonic development remains unclear. A developmental role is suggested by the presence of cPLA 2 activity in extracts of embryonic rat brain (27, 28) and by the embryonic expression of cyclooxygenase, an enzyme that utilizes the AA produced by PLA 2 activity for prostaglandin synthesis (29, 30) . Eicosanoids have also been implicated in chondrogenic differentiation, bone metabolism, and palate development (31) (32) (33) (34) . However, targeted gene inactivation in mice has failed to provide direct clues as to the developmental function of cPLA 2 activity. Mice deficient in a cPLA 2 homologue do not have gross developmental abnormalities although they are less likely to come to term (10, 11) . The lack of a morphological phenotype in these mice could be due to the expression and overlapping function of two other recently identified cPLA 2 homologues (35) .
As a first step in exploring the function of lipases in developing embryos, we have devised an assay to measure PLA 2 activity in embryonic extracts of the zebrafish, Danio rerio, utilizing BODIPY-labeled phosphatidylcholine (PC) as a substrate. By using this assay with different BODIPY-labeled sub-strates, and in the presence of various PLA 2 inhibitors, we have identified cPLA 2 as the principal enzymatic activity in zebrafish embryogenesis, and we characterized the developmental activity profile. The finding that cPLA 2 activity was the primary enzyme responsible for embryonic activity was confirmed by Western analysis of sucrose density gradient fractions. The zebrafish is an excellent model system to study vertebrate embryonic PLA 2 activity in vivo in that embryos are optically clear and experimentally accessible. These properties permit detection of enzymatic activity in living embryos using a quenched BODIPY-labeled PC that fluoresces upon cleavage by PLA 2 (36, 37) .
EXPERIMENTAL PROCEDURES
Materials-1,2-Dipalmitoylphosphatidylserine (DPPS), cholesterol, phosphatidylglycerol, phospholipase A 2 (Naja mossambica mossambica), phospholipase C (Bacillus cereus), and phospholipase D (type II, peanut) were obtained from Sigma. 2-(4,4-Difluoro-5,7-dimethyl-4-bora3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine (BODIPY C5-HPC; D-3803), 1-(O-(11-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl)amino)undecyl)-2-hexadecanoyl-sn-glycero-3-phosphocholine (D-7707), and 1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine (bis-BODIPY PC; B-7701) were obtained from Molecular Probes (Eugene, OR). Trifluoromethylarachidonyl ketone (AACOCF 3 ), methylarachidonyl fluorophosphonate (MAFP), and (E)-6-(bromo-methylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one (bromoenol lactone, BEL) were from Cayman Chemical Co. (Ann Arbor, MI). Phenylbutylmethyl fluorophosphonate (PMFP) and trifluoromethylelaidoyl ketone (ECOCF 3 ) were kindly provided by M. Gelb (University of Washington, Seattle, WA).
Zebrafish-Methods for breeding and raising zebrafish were followed as described (38) . Embryos were obtained from natural matings of wild-type fish and staged according to criteria previously outlined (39) .
Lipase Assay-Single embryos were placed in 0. (38) ), containing 150 -200 ng of a fluorescent phospholipid substrate, and sonicated for 2-5 s (6.3-cm cup horn, 100 watts; Heat Systems-Ultrasonics Inc. Plainview, NY). After 2-4 h at 37°C, reactions were stopped by the addition of 1.5 ml of chloroform/methanol (2:1) (40), mixed, and centrifuged (30 s, 16,000 ϫ g). The aqueous fraction was discarded, and the remaining lipid was dried under vacuum, resuspended in chloroform, and loaded on thin layer chromatography (TLC) plates (LK6D, Whatman, Clifton, NJ). Plates were developed in toluene, diethyl ether, ethanol, and acetic acid (50:40:2:0.2), and quantified using a laser scanner (blue laser, 800 V, Storm 860, Molecular Dynamics, Sunnyvale, CA).
Yolk Removal-Embryos (64-cell or shield stages) were placed in Petri dishes containing EM and examined under a dissecting stereomicroscope. The most posterior region of the yolk cell was pierced with number 5 watchmaker's forceps. The wound was gently reopened 1 or 2 times over the course of 10 -20 min until most of the yolk had flowed away from the blastoderm. Blastoderms were then rinsed in EM and assayed as described. Zebrafish lipids were added to some assays and were prepared as follows. Embryos (20 at shield stage) were homogenized in EM (50 l) by sonication; methanol (100 l) and chloroform (200 l) were added, and the solution was mixed and centrifuged (30 s, 16,000 ϫ g). The upper phase was discarded, and the lower phase was dried under a stream of N 2 . The lipids were resuspended in ethanol (2 l) followed by the immediate addition of EM (98 l). Either one embryo lipid equivalent (5 l of lipid solution) or a control solution (5 l of 2% ethanol in EM solution) was added to the assays.
Northern Analysis-cPLA 2 mRNA levels were detected by Northern analysis (41) using a 32 P-labeled cPLA 2 probe prepared by random priming (Prime-It II; Stratagene, La Jolla, CA) of gel purified (41) zebrafish cPLA 2 cDNA (2.5 kilobase pairs) excised from the PDE4 vector (Genetics Institute, Cambridge, MA).
Western Analysis-Zebrafish embryos were homogenized in buffer (50 mM Tris, pH 8.0, 80 mM NaCl, 1 mM EDTA, 1 mM EGTA), subjected to SDS-polyacrylamide gel electrophoresis, and detected by Western blotting using a polyclonal antiserum (1:1000) to human cPLA 2 (Genetics Institute, Cambridge, MA) and a goat anti-rabbit secondary (1:2000, Amersham Pharmacia Biotech). Immunoreactive bands were visualized by chemiluminescence (ECLϩ, Amersham Pharmacia Biotech). In some experiments, embryos were homogenized in buffer that also contained 5% sucrose and loaded on a linear sucrose gradient (2 ml, 5-23%) for centrifugation (2 h at 259,000 ϫ g). Fractions (130 l) were collected, and aliquots were assayed for total protein, PLA 2 activity, and by Western blotting as described above.
In Vivo PLA 2 Assay-Bis-BODIPY PC was purified by TLC to remove low abundance BODIPY-labeled degradation products immediately prior to incorporation into liposomes. The liposome composition that yielded the best quenching was based on two previously published protocols (36, 37) . Briefly, a mixture of DPPS/cholesterol/phosphatidylglycerol/bis-BODIPY PC (107:31:20:1; a total of 287 nmol) was dried under N 2 and resuspended in ethanol (10 l) followed by the addition of EM (10 l). The solution was again dried under N 2 until the volume was approximately 7 l to ensure the evaporation of most of the ethanol. EM (0.15 ml) was added, and liposomes were prepared by sonication of the mixture on ice (20 min, probe type). Liposomes were incubated with dechorionated gastrulating embryos (2-4 h at 28°C; 20 l/embryo). Embryos were rinsed with EM and placed in a glass depression slide. Fluorescence was visualized using a Leica TCSNT confocal microscope.
RESULTS
Zebrafish Embryonic PLA 2 Activity Is Detected Using a Fluorescent Assay-We have developed a sensitive assay for PLA 2 activity that utilizes a PC substrate containing a BODIPYlabeled fatty acid on the sn-2 position. Cleavage of this lipid by PLA 2 liberates a fluorescent fatty acid that is readily separated from the uncleaved substrate on TLC plates and quantified by laser scanning. The addition of purified PLA 2 (N. mossambica mossambica) to the assay buffer (EM ϩ substrate) resulted in complete cleavage of the substrate, detected as the appearance of a band on the TLC plate that co-migrates with free BODIPYlabeled fatty acid (Fig. 1A, lane 1) , the expected product of PLA 2 activity (Fig. 1A, lane 2) . To test whether other phospholipases generate products that also co-migrate with the free BODIPY-labeled fatty acid, we examined the cleavage products of purified phospholipase C and phospholipase D in the assay. Samples incubated with phospholipase C produced a distinct fluorescent diacylglycerol species that was easily resolved from the free BODIPY-labeled fatty acid (Fig. 1A, lane 3) . The expected product of phospholipase D activity, a fluorescent phosphatidic acid species, migrated with the uncleaved PC substrate and not with the free fatty acid generated by PLA 2 (data not shown). In samples without added enzyme, we observed a consistent small amount of nonenzymatic hydrolysis of the substrate (0.03-0.05% of the substrate/h) which is 10 -100-fold less than that observed with samples containing PLA 2 (Fig. 1A , lane 5). For this reason, all experiments included at least one control incubation that consisted of assay buffer alone. Following quantification of the TLC plate, the fluorescence of this control reaction was used as the base line for all samples.
By using this assay, PLA 2 activity could be detected in extracts of single zebrafish embryos (Fig. 1A, lane 4) . Zebrafish PLA 1 activity was not detected in these assays using a TLC solvent system that resolves fluorescent lyso-PC (the expected product of PLA 1 ) from the fluorescent PC substrate (data not shown). To test whether any PLA 2 was inactivated during the incubation period (typically 2-3 h), zebrafish embryonic extracts were assayed for various lengths of time. The rate of substrate cleavage was independent of assay duration for more than 7 h (Fig. 1B) , indicating that the PLA 2 activity in zebrafish embryonic extracts was stable.
PLA 2 Activity Is Predominantly in the Cellular Blastoderm of the Gastrulating Embryo-Shortly after fertilization, the zebrafish zygote segregates into two domains, the dividing cells (blastodisc) atop a yolk cell (39) . The blastodisc divides multiple times generating a cellular blastoderm (approximately 4000 cells) that continues to divide while migrating over the large (ϳ700-m diameter) yolk cell in a process termed epiboly (42) . Based on the yolk composition of other teleosts (43, 44) , the zebrafish yolk likely contains lipoproteins and lipids. The ob-served PLA 2 activity of the zebrafish embryo might serve the following two functions: it could be associated with degradation of yolk lipid for a nutritive purpose, or it could be a mediator of cell signaling in the blastoderm. To distinguish between these possibilities, the yolk was separated from the overlying blastoderm by piercing the yolk cell and extruding the yolk ( Fig. 2A) . Levels of PLA 2 activity in the blastoderm and intact embryo were then compared. Whereas we observed a small reduction in activity after yolk removal in embryos assayed at the 64 -128-cell stage (31 Ϯ 5%), no reduction was observed in shield stage embryos (6 h post-fertilization, approximately 16,000 cells) (Fig. 2B) . Shield stage embryos and blastoderms were also assayed in the presence of additional zebrafish lipids to quantify the activity in the blastoderm and the levels of endogenous zebrafish lipid that can compete in the assay (Fig. 2B , and see "Appendix"). Modeling of these data indicate that the yolk contains no PLA 2 activity at shield stage (see "Appendix") and suggests that embryonic activity primarily mediates cell signaling in the blastoderm rather than yolk lipid processing.
cPLA 2 Is the Principal Activity Detected in Zebrafish Embryonic Extracts-To characterize the phospholipase activity present in zebrafish embryos, we utilized the fluorescent TLC assay to analyze substrate preference, calcium dependence, and response to specific inhibitors. Two substrates with different acyl chains were useful to distinguish between activity due to sPLA 2 or to cPLA 2 /iPLA 2 (D-7707 contains a 14-carbon saturated fatty acid on the sn-2 position and a BODIPY-labeled fatty acid on the sn-1 position, and D-3803 contains a BODIPYlabeled saturated fatty acid on the sn-2 position and an unlabeled fatty acid on the sn-1 position) (Fig. 3A) . sPLA 2 is known to exhibit little specificity for particular acyl chains, and accordingly, purified snake enzyme cleaved both substrates in the assay (Fig. 3B, lane 2 
upper arrow and lane 5, lower arrow).
In contrast, purified human cPLA 2 showed a strong preference for D-3803 (Fig. 3B, lane 3) over D-7707 (Fig. 3B, lane 6) . The BODIPY-labeled acyl chain of D-3803 was cleaved by cPLA 2 30-fold more readily than was saturated fatty acid of D-7707 (Fig. 3A, lane 3 versus lane 6) .
When D-3803 was used a substrate, there was a linear relationship between enzyme concentration and the level of PLA 2 cleavage product; as little as 20 ng of human cPLA 2 extract generated significant BODIPY-labeled fatty acid (3-fold greater than blank, Fig. 3C ). This level of activity is in the range of that previously observed for cleavage of phospholipids containing radiolabeled AA (22) and confirms our observation that the affinity of cPLA 2 for, and cleavage of, D-3803 is comparable to that of endogenous cPLA 2 substrates. We hypothesize that the hydrophobic BODIPY moiety at the sn-2 position disrupts the 
FIG. 2. Zebrafish cPL A 2 activity is localized to the blastoderm.
The yolk was removed from shield stage zebrafish embryos, and resultant blastoderms were incubated in 200 l of EM containing D-3803 (120 pmol/reaction; 1 h) and assayed as described under "Experimental Procedures." A, intact shield stage zebrafish embryo (left). Blastoderm with yolk removed (right). B, PLA 2 activity in the intact embryo compared with the yolkless blastoderm. Prior to the start of the experiment, embryo lipids were extracted as described under "Experimental Procedures" and added to some assays. Data represent means Ϯ S.E., n ϭ 3.
local membrane environment in a fashion similar to AA.
The substrate preference of the enzymatic activity present in zebrafish extracts (Fig. 3D) was more similar to that of the purified human cPLA 2 (D-3803 is cleaved to release a BODIPYfatty acid, whereas D-7707 is not cleaved), suggesting that zebrafish embryos do not contain significant sPLA 2 activity.
Consistent with this observation, extract PLA 2 activity was not significantly inhibited by dithiothreitol (10 mM), a potent sPLA 2 inhibitor (treated embryos had 87 Ϯ 9% of control activity, n ϭ 3, p Ͼ 0.4).
Since cPLA 2 and some iPLA 2 s can exhibit similar acyl chain preferences, comparisons of the cleavage rates of different sub- strates is insufficient to discriminate between their activities. One defining characteristic of iPLA 2 s is their Ca 2ϩ independence. The PLA 2 activity in zebrafish embryonic extracts was reduced by greater than 80% (Fig. 4A ) with the removal of free Ca 2ϩ through the addition of EGTA (10 mM), suggesting that the activity was predominantly due to cPLA 2 and not iPLA 2 .
To confirm this observation, zebrafish extracts were incubated with a panel of PLA 2 inhibitors that are known to exhibit different relative potencies for the two classes of enzyme. MAFP, an irreversible inhibitor of cPLA 2 that is believed to form a covalent bond with serine 228 of the catalytic site (45), was a potent inhibitor of the zebrafish extract activity (Fig. 4B) . Similarly, the well characterized competitive cPLA 2 inhibitor AACOCF 3 (46, 47) was also effective in blocking extract activity (Fig. 4C) . The substitution of the arachidonyl moiety of MAFP with a phenyl-butyl group (PMFP) or the arachidonyl moiety of AACOCF 3 with an elaidoyl moiety (ECOCF 3 ) yields inhibitors that are more potent against iPLA 2 .
2 However, these modified inhibitors were less effective than their arachidonyl versions at inhibiting extract activity (Fig. 4, B and C) . In sum, the ranked potency of PLA 2 inhibitors for zebrafish extracts (MAFP (ED 50 2 nM) Ͼ PMFP (ED 50 200 nM) Ͼ AACOCF 3 (ED 50 15 M) Ͼ ECOCF 3 (ED 50 30 M)) more closely paralleled that expected for cPLA 2 than that expected for iPLA 2 (PMFP Ͼ MAFP Ͼ ECOCF 3 Ͼ AACOCF 3 ).
An additional inhibitor, BEL, is a potent and irreversible inhibitor of iPLA 2 that can also inhibit cPLA 2 , but only at higher doses (14) . In zebrafish extracts, BEL was 1000 times less effective an inhibitor of PLA 2 activity than MAFP. Moreover, inhibition of the zebrafish activity required 50-fold higher doses than reported for purified iPLA 2 (48, 49) (Fig. 4D) . Taken together, the pharmacological profile of the PLA 2 activity in the zebrafish embryo is most consistent with the cPLA 2 subtype.
Developmental Profile of PLA 2 Activity and cPLA 2 Gene Expression-PLA 2 activity in lysates was characterized during different stages of zebrafish embryonic development. The activity observed at the 1-cell stage reflects a significant maternal contribution of cPLA 2 protein to the embryo (note that zygotic transcription does not begin until the 1000-cell stage) (Fig. 5B) . Activity remained constant from the 1-cell to 4-somite stage and then increased, reaching 250% of initial levels in 24-h-old embryos. However, total embryonic protein levels remained unchanged during this period (at the 1-cell stage 27.1 Ϯ 0.3 g/embryo and after 24 h 24.2 Ϯ 2.1 g/ embryo). PLA 2 activity continued to climb to levels 8-fold greater than 1-cell stage embryos by 50 h post-fertilization.
To correlate embryonic PLA 2 activity with cPLA 2 gene expression, we measured the RNA level of a zebrafish cPLA 2 homologue (1). To date, only this cPLA 2 homologue has been described for zebrafish; however, additional closely related genes are expected to be found (50) . We examined expression of this gene in relation to the enzymatic activity profile. A North-2 M. Gelb, personal communication. ern blot produced from RNA of staged zebrafish embryos revealed a 9.7-kilobase pair transcript that was weakly detected at the end of gastrulation but rapidly increased to a constant level throughout somitogenesis (Fig. 5A) . Whereas the rise in zebrafish extract PLA 2 activity (between 12 and 20 h) was preceded by the expression of this cPLA 2 homologue (initially detected at 9 h), we cannot rule out that the products of other zebrafish cPLA 2 homologues contribute to extract activity.
cPLA 2 Immunoreactivity Co-migrates with PLA 2 Activity-To confirm that the zebrafish activity was due to cPLA 2 , embryonic extracts were subject to SDS-polyacrylamide gel electrophoresis and Western blot analysis using antiserum to human cPLA 2 (Fig. 6) . The cross-reactive antiserum detects the predominant zebrafish product as a single 85-kDa band (lower arrow, lane 2). We were unable to test the activity associated with this band because cPLA 2 activity from both zebrafish extracts and purified human protein was poorly reconstituted from gel or nitrocellulose fragments. However, extracts were subject to sucrose gradient sedimentation, and fractions were assayed for PLA 2 activity, total protein, and cPLA 2 immunoreactive product. Activity was observed primarily in fractions 2-4, whereas much of the total protein was contained in fractions 3-5 (Fig. 6B ). More importantly, cPLA 2 immunoreactive bands were only detected in fractions that had high levels of PLA 2 activity (Fig. 6C) .
PLA 2 Activity Localizes to Intracellular Membranes in Vivo-We sought to develop an in vivo reporter of PLA 2 activity to visualize enzymatic activity in living zebrafish embryos. Previously, a quenched BODIPY-labeled PC (Bis-BODIPY FL C11-PC) had been used to visualize PLA activity in cultured neutrophils (36) . Bis-BODIPY FL C11-PC is a molecule similar to D-3803 with an additional BODIPY moiety added to the acyl chain on the sn-1 position. When Bis-BODIPY FL C11-PC is incorporated into cell membranes, the close proximity of the two BODIPY-labeled acyl chains attenuates fluorescence due to energy transfer between the fluorophores (36). Upon cleavage by PLA 2 , one of the BODIPY-labeled acyl chains is released from the membrane, thereby separating the two BODIPY moieties and increasing fluorescence. In light of this work and our finding that BODIPY-labeled acyl chains are cleaved by cPLA 2 , we tested whether quenched Bis-BODIPY FL C11-PC could label living zebrafish embryos and act as an in vivo biosensor of PLA 2 activity.
To incorporate the quenched fluorophore, live blastula stage embryos (4 h post-fertilization) were soaked in liposomes containing Bis-BODIPY FL C11-PC. The addition of cholesterol to the liposomes was found to quench the fluorophore more effectively, and the use of DPPS, as opposed to PC, helped facilitate the movement of the fluorophore to the inner leaflet of the plasma membrane (data not shown). Immediately following liposome labeling, fluorescence could be detected under low power using an epifluorescence stereomicroscope (Fig. 7) .
To test whether the observed fluorescence truly reflected PLA 2 activity, embryos were labeled in the presence of the cPLA 2 inhibitor MAFP. The concentration of MAFP needed to inhibit cPLA 2 activity in an intact embryo was determined by bathing embryos in various concentrations of MAFP for 2 h, washing away the inhibitor, and lysing the embryos for the standard PLA 2 assay. When MAFP was added after an embryo had been lysed and sonicated in assay buffer (0.2-0.5 ml), PLA 2 activity was inhibited with an ED 50 of 2 nM (Fig. 4B) . However, if an intact living embryo was soaked in MAFP for 2 h, a concentration of 5 M was required to inhibit 81 Ϯ 9% (n ϭ 3) of the PLA 2 activity. Incubation of embryos with liposomes in the presence of MAFP (5 M) inhibited specific fluorescent labeling of embryonic cells visualized either at low power using an epifluorescence stereomicroscope (n ϭ 3, 3-5 embryos/group/experiment; Fig. 7A ) or using a confocal microscope (data not shown).
We ruled out that this inhibition was due to nonspecific effects of MAFP treatment since incubation of liposomes containing D-3803 in the presence of MAFP (5 M) had no effect on the extensive fluorescence observed with this unquenched BODIPY PC (n ϭ 2, 3-5 embryos/experiment; data not shown).
The subcellular localization of the fluorescence was examined using confocal microscopy. PLA 2 -induced fluorescence was observed in perinuclear and nuclear membranes of embryonic cells, consistent with the localization of cPLA 2 protein in activated tissue culture cells (21) (Fig. 7B) . In all experiments, perinuclear and nuclear labeling was observed (n ϭ 6, 3-9 embryos/experiment); however, not all cells showed equal levels of PLA 2 activity. This pattern of labeling was blocked by MAFP, indicating that the perinuclear labeling observed in living embryos is due to PLA 2 activity. DISCUSSION PLA 2 enzymes hydrolyze phospholipids, thereby releasing molecules that can mediate a number of important cellular processes, yet the regulation and function of PLA 2 activity during embryonic development remains unclear. We have devised a sensitive PLA 2 assay utilizing a BODIPY-labeled PC that requires few experimental manipulations and yields reliable quantitative data on the activity present in embryonic extracts. The assay exploits new advances in laser scanning technology to quantify fluorescent products on TLC plates and is sensitive enough to detect PLA 2 activity from single zebrafish embryos. This is the first time PLA 2 activity has been characterized in the developing zebrafish, a powerful model system to study vertebrate development by both visual and genetic means. The development of this fluorescent PLA 2 assay provides the basis of future studies to understand the role of embryonic activity.
The assay we developed facilitated the characterization of the PLA 2 activity in zebrafish embryos and indicated that the predominant activity is due to cPLA 2 . First, the TLC-based assay was used to characterize the acyl chain specificity of zebrafish PLA 2 activity and to demonstrate that embryonic extracts exhibited an acyl chain preference and a dithiothreitol insensitivity incompatible with sPLA 2 activity. By using two distinct BODIPY-labeled PC substrates, we found that the PLA 2 activity in zebrafish extracts has a 30-fold higher preference for phospholipid with a BODIPY-labeled acyl chain on the sn-2 position over an sn-2 saturated fatty acid. Consistent with this observation, Clark et al. (22) observed that cPLA 2 preferred arachidonyl phospholipids almost 20-fold over phospholipids containing other sn-2 fatty acids in membranes from U937 cells (22) . Thus, the acyl chain preference of zebrafish of a 24 h embryo) of zebrafish extract (lane 2) was subject to SDS-polyacrylamide gel electrophoresis and detected by Western blotting using antiserum to human cPLA 2 . The sizes of molecular mass standards are given in kilodaltons. B, zebrafish extract (200 -300 g) was loaded on a linear sucrose gradient as described under "Experimental Procedures." Fractions were collected, and aliquots were assayed for total protein and PLA 2 activity. Data represent a means Ϯ S.E. of 3 experiments. C, 35 l of each fraction were mixed with sample buffer, boiled, and assayed for cPLA 2 immunoreactivity as described above. Data shown are from a typical experiment. Human cPLA 2 protein (std; 2 ng) was loaded in the far right lane.
extract activity is similar to that observed with purified human cPLA 2 and unlike that of sPLA 2 .
Since both cPLA 2 and the 28 -40-kDa iPLA 2 s exhibit acyl chain preferences for AA, pharmacologic experiments were performed to distinguish between the contributions of their activities in zebrafish embryos. The observation that EGTA blocked more than 80% of substrate cleavage suggested that the zebrafish embryonic activity was predominantly due to cPLA 2 . To rule out potential nonspecific effects of EGTA, a panel of competitive and irreversible PLA 2 inhibitors was tested. The activity profile in the presence of these reagents confirmed that cPLA 2 was the major PLA 2 activity in zebrafish embryonic extracts.
The TLC assay was also used to examine the compartmentalization of PLA 2 activity within the embryo. Experiments on deyolked embryos suggested that PLA 2 activity localizes primarily to the developing blastoderm after 6 h of development. The observation that some activity is lost (Ͻ35%) when the yolk is removed from younger embryos leaves open the possibility of an early role for PLA 2 activity in the yolk. The level of endogenous PLA 2 substrate (3 pmol/g), determined by modeling the effect of adding exogenous zebrafish lipids to the assay (see "Appendix"), was consistent with the levels of arachidonyl-PC (approximately 3-5 pmol/g) observed in the embryos of other teleosts (43, 44) . These data are consistent with the endogenous embryonic substrate being arachidonyl-PC, the ideal cPLA 2 substrate.
A number of questions remain regarding the origin of enzymatic activity (maternal versus zygotic) and the relative contributions of different cPLA 2 isoforms that comprise zebrafish embryonic PLA 2 activity. Expression of a zebrafish cPLA 2 homologue is detected approximately 6 h after the onset of zygotic transcription and at least 2 h before total embryonic PLA 2 activity begins to increase. We also found that cPLA 2 activity sediments as a single peak by sucrose gradient centrifugation, a peak that also contains the predominant cPLA 2 species detected by Western blot analysis. Absolute identification of the cPLA 2 isoform(s) responsible for embryonic activity awaits the cloning of other zebrafish cPLA 2 family members and the generation of isoform-specific antibodies for immunodepletion experiments.
The substrate specificity, pharmacological profile, and the immunoblotting experiments indicate that zebrafish embryo extracts contain at least one cPLA 2 homologue and that this homologue, possibly in conjunction with other cPLA 2 family members, is responsible for most of the embryonic activity.
The zebrafish is an ideal vertebrate model system to study biochemical processes during development because its embryos are rapidly developing, accessible, and optically clear. These properties facilitate the use of fluorescently quenched lipid probes that can directly report PLA 2 activity in living embryos. By having established that PC containing a BODIPY-labeled acyl chain on the sn-2 position was a good substrate for cPLA 2 , we utilized a double-labeled and fluorescently quenched BODIPY PC to examine the subcellular localization of cPLA 2 activity in living embryos. Cleavage of this fluorophore by either PLA 1 or PLA 2 results in enhanced fluorescence (36, 37) . In zebrafish extracts, any increase in fluorescence was expected to reflect cPLA 2 activity. Upon incorporation of the lipid fluorophore into cell membranes, PLA 2 activity is expected to result in two fluorescent species as follows: a diffusible free fatty acid and a fluorescent lysolipid that is assumed to be less mobile (and would probably be rapidly reacylated to form a fluorescent PC).
Laser confocal microscopy revealed PLA 2 activity in the outermost embryonic cells, known as the enveloping layer. The absence of a signal from deeper cell layers probably does not imply low cPLA 2 activity in these regions but rather reflects the failure of the fluorophore to penetrate the embryo. In the enveloping layer, PLA 2 activity was localized to regions surrounding the nuclear envelope. This observation is consistent with reports by Glover et al. (21) , who used anti-cPLA 2 antiserum followed by immunogold electron microscopy to localize cPLA 2 protein in stimulated tissue culture cells to the perinuclear region.
The cPLA 2 inhibitor MAFP had no effect on the incorporation of an unquenched fluorescent substrate, yet it completely blocked the perinuclear labeling observed using the quenched PLA 2 activity reporter. These data strongly suggest that the observed fluorescence truly reflects PLA 2 activity.
Our current data provide evidence of significant PLA 2 activity in the blastoderm of developing zebrafish embryos. This activity increases during development and is almost entirely due to cPLA 2 . These data also indicate that cPLA 2 activity can be monitored using BODIPY-labeled acyl chains in both in vitro and in vivo continuous lipase assays. Recently, we have used these assays in a genetic screen for modifiers of PLA 2 activity FIG. 7. Localized cPLA 2 activity is detected in enveloping layer cells in vivo. PLA 2 activity was observed in zebrafish gastrulas that had been incubated with liposomes containing 1,2-bis-BODIPYphosphatidylcholine for 2 h, as described under "Experimental Procedures." Embryos were visualized at the end of gastrulation (100% epiboly) using a stereomicroscope equipped with epifluorescence. Embryos exhibited fluorescence immediately after labeling. A, addition of MAFP (5 M) to the liposomes completely inhibited cellular fluorescence. B, subcellular localization of fluorescence was visualized using laser confocal microscopy. PLA 2 activity was observed in the cells of the enveloping layer, predominantly in the perinuclear membranes.
and are now analyzing potential mutants. We are also developing methods to label living embryos more effectively, with the goal of examining PLA 2 signaling in real-time and correlating activity with specific developmental events.
APPENDIX
To estimate the PLA 2 activity in the yolk and blastoderm, assays were performed with and without the addition of one embryo's equivalent of zebrafish lipid (see "Experimental Procedures"). The amount of BODIPY-PC cleaved by an extract containing an intact embryo was determined experimentally to be 12 Ϯ 2 pmol, a blastoderm was 16 Ϯ 2 pmol, an embryo plus additional embryo lipid was 8.7 Ϯ 0.5 pmol, and a blastoderm plus additional lipid was 10.7 Ϯ 0.1 pmol (Fig. 2B) . These data were used to determine the amount of PLA 2 activity in the yolk and the blastoderm, and the levels of endogenous lipids that can compete for the fluorescent substrate by solving the Equations 1-4, 
